Phoenix Financial Ltd. Sells 41,678 Shares of Brainsway Ltd. Sponsored ADR $BWAY

Phoenix Financial Ltd. trimmed its holdings in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 10.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 362,316 shares of the company’s stock after selling 41,678 shares during the period. Phoenix Financial Ltd. owned 1.92% of Brainsway worth $4,764,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BWAY. GAMMA Investing LLC increased its holdings in Brainsway by 720.7% in the first quarter. GAMMA Investing LLC now owns 9,356 shares of the company’s stock valued at $89,000 after purchasing an additional 8,216 shares during the last quarter. Palumbo Wealth Management LLC acquired a new position in shares of Brainsway during the 1st quarter worth about $111,000. Trexquant Investment LP acquired a new position in shares of Brainsway during the 1st quarter worth about $129,000. NewEdge Advisors LLC increased its stake in shares of Brainsway by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after acquiring an additional 7,549 shares during the last quarter. Finally, Eagle Global Advisors LLC acquired a new stake in shares of Brainsway in the 1st quarter valued at approximately $590,000. 30.11% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on BWAY. Northland Securities upped their target price on shares of Brainsway from $15.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 17th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Brainsway in a research note on Monday, August 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Brainsway in a report on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Brainsway Stock Performance

NASDAQ:BWAY opened at $16.28 on Wednesday. Brainsway Ltd. Sponsored ADR has a 52-week low of $7.84 and a 52-week high of $17.00. The company has a market cap of $309.32 million, a P/E ratio of 62.62 and a beta of 1.23. The stock’s 50-day simple moving average is $15.31 and its 200 day simple moving average is $12.29.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.03. The firm had revenue of $12.63 million during the quarter, compared to the consensus estimate of $12.34 million. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. Brainsway has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current fiscal year.

Brainsway Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.